Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine

• Published in: Endocrine, metabolic & immune disorders drug targets Vol. 21; no. 6; p. 971
• Main Authors: Wang, Shengju, Xu, Zhang, Cai, Baochao, Chen, Qiu
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2021
• Subjects: Animals; Berberine - administration & dosage; Berberine - metabolism; Drug Delivery Systems - methods; Drug Delivery Systems - trends; Gastrointestinal Microbiome - drug effects; Gastrointestinal Microbiome - physiology; Humans; Insulin Resistance - physiology; Metabolic Diseases - drug therapy; Metabolic Diseases - metabolism; Oxidative Stress - drug effects; Oxidative Stress - physiology; chronic inflammatory; Berberine; metabolic disorders; nonalcoholic fatty liver disease; type 2 diabetes; insulin resistance; intestinal flora
• ISSN: 2212-3873
• DOI: 10.2174/1871530320666200910105612

Berberine (BBR) is a botanic alkaloid extracted from Coptis chinensis (Huanglian), which has various properties, compassing anti-hyperglycemia, anti-obesity, anti-inflammation, and improves insulin resistance, etc. Several researches have confirmed that BBR has effective actions in treating glycolipid metabolic abnormalities. BBR is also beneficial in regulating intestinal flora. Metabolic diseases are strongly associated with metabolic disorders, which are growing in the population and dramatically impacting human health, which also have been considered as a leading cause of diseases and death globally. This review is to evaluate the metabolic properties of BBR, and its potential application to the treatment of metabolic diseases by its effective actions on metabolic disorders.